Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Ryan G Keddy

Tammie K Jinkerson

Charles W Hutchins

David A DeGoey

Warren M Kati

Pamela L Donner

Kevin R Woller

John T Randolph

Allan C Krueger

Sachin V Patel

Christopher E Motter

John K Pratt

Rolf Wagner

Todd Warren Rockway

Dachun Liu

David A Betebenner

Douglas K Hutchinson

Clarence J Maring

Charles A Flentge

Michael D Tufano

Yi Gao

William A Carroll

Philip R Kym

Arthur Gomtsyan

Anil Vasudevan

Michael E Kort

Wilfried Hornberger

Helmut Mack

Michael J Dart

Jerome F Daanen

Adrian Hobson

Brian S Brown

Eric A Voight

Chih-hung Lee

Clara I Villamil

Gregory A Gfesser

Sridhar Peddi

Derek W Nelson

Tami J Pilot-Matias

Mark A Matulenko

Lissa T Nelson

Kathy A Sarris

Seble H Wagaw

Wenke Li

Daniel D Caspi

Mary E Bellizzi

Jean C Califano

Daryl Richard Sauer

Nicole Teusch

Jean-Christophe C Califano

Dominique Bonafoux

Michael F Jarvis

Robert G Schmidt

Bernhard K Mueller

Bruce Clapham

Anurupa Shrestha

Phil B Cox

Preethi Krishnan

David A Degoey

Todd N Soltwedel

Steven Lewis Swann, Jr

Neeta C Mistry

Steve Swann, Jr

Bernhard K Muller

Gao Yi

DanielD Caspi

Hutchinson Douglas K K

Krueger Allan C C

Douglas H Hutchinson

Sebel H Wagaw

Sachel V Patel

Teresa Ng

Thomas J Reisch

Teresa (lok-Chan) Ng

Kathy Sarris

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). Rand Rare, independently of each other, hydrogen, hydroxy, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy or C-C-haloalkoxy; R, R, Rand Rare, independently of each other, hydrogen, hydroxy, halogen, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy, C-C-haloalkoxy, amino, C-C-alkylamino or di-(C-C-alkyl)-amino; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, aryl or aryl-C-C-alkyl; Ris a group of the formula &#x2014;X&#x2014;W, where X is a single bond, C-C-alkylene or C-C-alkylene-O&#x2014;, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; Ris a group of the formula &#x2014;Y&#x2014;Z, where Z is hydrogen, halogen, OR, NRR, S(O)&#x2014;R, phenyl which may carry 1, 2, 3 or 4 substituents Ror a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched CC-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond. 

4-(4-pyridinyl)-benzamides and their use as rock activity modulators

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, and R, are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Amide derivatives as TRPV1 antagonists

Growing community of inventors

Beach Park, IL, United States of America

Ryan G Keddy